Entrada Therapeutics, Inc.

TRDA Nasdaq SEC CIK 1689375
Follow Entrada Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $905K −43.9% vs same quarter last year
Net income −$39.7M +10% vs same quarter last year
EPS, diluted −$0.94 +11.3% vs same quarter last year
Operating cash flow −$30M −5.8% vs same quarter last year
Revenue by quarter
$37.4M
$20.6M
$2M
$1.6M
$1.3M
$875K
$898K
$905K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100M$200M$300MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$25.4M−$143.8M
FY24$210.8M$65.6M
FY23$129M−$6.7M
FY22-−$94.6M
FY21-−$51.2M
FY20-−$26.5M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−800%−600%−400%−200%0%200%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−621.1%−565.5%
FY2422.3%31.1%
FY23−2.5%−5.2%
FY22--
FY21--
FY20--
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100M$200MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$129.6M
FY24−$44.7M
FY23$134.2M
FY22−$96.7M
FY21−$55.4M
FY20−$27.9M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Entrada Therapeutics
  • Healthcare median
−600%−400%−200%0%200%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearEntrada TherapeuticsHealthcare median
FY25−565.5%−30.6%
FY2431.1%−47%
FY23−5.2%−58%
FY22-−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%